Cytokinetics, Incorporated
Stock Forecast, Prediction & Price Target
Cytokinetics, Incorporated Financial Estimates
Cytokinetics, Incorporated Revenue Estimates
Cytokinetics, Incorporated EBITDA Estimates
Cytokinetics, Incorporated Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $70.42M N/A | $94.58M 34.30% | $7.53M -92.03% | Avg: $72.93M Low: $4.77M High: $267.01M avg. 868.53% | Avg: $383.80M Low: $23.15M High: $1.21B avg. 426.25% | Avg: $903.98M Low: $54.53M High: $2.86B avg. 135.53% | Avg: $1.55B Low: $93.92M High: $4.94B avg. 72.21% |
Net Income
% change YoY
| $-242.37M N/A | $-402.55M -66.08% | $-526.24M -30.72% | Avg: $-494.03M Low: $-588.79M High: $-258.68M avg. 6.12% | Avg: $-317.72M Low: $-569.49M High: $-4.32M avg. 35.68% | Avg: $35.39M Low: $-7.84M High: $135.42M avg. 111.13% | Avg: $332.62M Low: $-73.69M High: $1.27B avg. 839.80% |
EBITDA
% change YoY
| $-185.98M N/A | $-312.86M -68.22% | $-456.68M -45.97% | Avg: $-72.93M Low: $-267.01M High: $-4.77M avg. 84.03% | Avg: $-383.80M Low: $-1.21B High: $-23.15M avg. -426.25% | Avg: $-903.98M Low: $-2.86B High: $-54.53M avg. -135.53% | Avg: $-1.55B Low: $-4.94B High: $-93.92M avg. -72.21% |
EPS
% change YoY
| -$3.15 N/A | -$4.48 -42.22% | -$5.45 -21.65% | Avg: -$4.42 Low: -$6.1 High: -$2.68 avg. 18.95% | Avg: -$2.73 Low: -$5.9 High: -$0.04 avg. 38.11% | Avg: $0.37 Low: -$0.08 High: $1.4 avg. 113.41% | Avg: $3.45 Low: -$0.76 High: $13.19 avg. 839.80% |
Operating Expenses
% change YoY
| $96.80M N/A | $177.97M 83.85% | $173.61M -2.45% | Avg: $419.09M Low: $27.44M High: $1.53B avg. 141.39% | Avg: $2.20B Low: $133.06M High: $7.00B avg. 426.25% | Avg: $5.19B Low: $313.40M High: $16.48B avg. 135.53% | Avg: $8.94B Low: $539.73M High: $28.39B avg. 72.21% |
FAQ
What is Cytokinetics, Incorporated stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 248.18% in 2025-2028.
We have gathered data from 13 analysts. Their low estimate is -588.79M, average is -494.03M and high is -258.68M.
What is Cytokinetics, Incorporated stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 375.63% in 2025-2028.
We have gathered data from 13 analysts. Their low revenue estimate is $4.77M, average is $72.93M and high is $267.01M.
What is Cytokinetics, Incorporated stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 252.57% in 2025-2028.
We have gathered data from 13 analysts. Their low earnings per share estimate is -$6.1, average is -$4.42 and high is $-2.68.
What is the best performing analyst?
In the last twelve months analysts have been covering Cytokinetics, Incorporated stock. The most successful analyst is Joseph Pantginis whose win rate is 33.33%. He has correctly predicted 1/3 price targets.